Srinath Kadimi, MD
Neurology · Fairfield, CTNPI 1730144734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,594 of the $31,513 with a category attached, or 74.9%. AbbVie accounts for 76.2% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2021 at $11,143 and has fallen 99.7% since, to $29 in 2023.
Across 250 payments — averaging $126.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- AstraZeneca$3K
- Eisai Inc.$1K
- Medtronic$580
- Biogen$394
- Johnson & Johnson$299
- plus $2K from 30 others
Across 102 payments — averaging $8589.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$558K
- Genentech, Inc.$208K
- Biogen$64K
- Novo Nordisk AS$20K
- AbbVie$17K
- Eisai Inc.$9K
What the payments were for
- Speaking & faculty fees$23,59475%
- Travel & lodging$3,42211%
- Food & beverage$4,46714%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $23,998 |
| AstraZeneca | 8 | $2,943 |
| Eisai Inc. | 13 | $1,270 |
| Medtronic | 5 | $580 |
| Biogen | 22 | $394 |
| Johnson & Johnson | 6 | $299 |
| Teva Pharmaceuticals USA, Inc. | 17 | $237 |
| EMD Serono, Inc. | 19 | $227 |
| UCB, Inc. | 12 | $151 |
| Novartis | 12 | $135 |
| Acorda Therapeutics, Inc | 11 | $127 |
| Adamas Pharmaceuticals, Inc. | 9 | $121 |
| MDD US Operations, LLC | 3 | $87 |
| Lundbeck LLC | 4 | $79 |
| Merz North America, Inc. | 5 | $66 |
| Sanofi | 4 | $65 |
| Assertio Therapeutics, Inc. | 4 | $63 |
| Acadia Pharmaceuticals Inc | 5 | $59 |
| Alnylam Pharmaceuticals Inc. | 3 | $57 |
| Promius Pharma LLC | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 4 | $53 |
| Vertical Pharmaceuticals, LLC | 3 | $49 |
| Avanir Pharmaceuticals, Inc. | 4 | $49 |
| Amneal Pharmaceuticals LLC | 3 | $48 |
| Boston Scientific | 1 | $45 |
| Akcea Therapeutics, Inc. | 2 | $42 |
| CSL Behring | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Pfizer | 2 | $26 |
| Amgen | 2 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Upsher-smith Laboratories LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,513 in reported general payments places this provider in the 85th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 14 | $15,260 |
| Rasagiline Mesylate | 47 | $12,610 |
| Memantine Hcl | 289 | $10,909 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 22 | $8,228 |
| Levetiracetam | 271 | $6,666 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 311 | $5,729 |
| Mycophenolate Mofetil | 19 | $5,039 |
| Donepezil Hcl | 406 | $4,018 |
| Gabapentin | 131 | $3,431 |
| Primidone | 68 | $3,240 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 44 | $2,726 |
| Lacosamide | 18 | $2,572 |
| Divalproex Sodium | 39 | $1,657 |
| Carbamazepine | 35 | $1,459 |
| AmantadineAmantadine Hcl | 18 | $1,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $23,998 | $15,26014 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $48 | $6,06031 claims |
| Upsher-smith Laboratories LLCTopiramate | $13 | $1,13292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 280 neurology providers in Connecticut.
Other neurology in Fairfield
- Peter McAllisterFairfield$2.3M
- Peter GottschalkFairfield$318K
- Nicholas BlondinFairfield$93K
- Jeffrey GrossFairfield$52K
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.